ID

16954

Description

Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00375791

Lien

https://clinicaltrials.gov/show/NCT00375791

Mots-clés

Versions (2)
  1. 16/08/2016 16/08/2016 -
  2. 16/08/2016 16/08/2016 - Julian Varghese
Téléchargé le

16 août 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Multiple Myeloma NCT00375791

Anglais

Eligibility Multiple Myeloma NCT00375791

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. plasmacytomas on tissue biopsy.
Description

Criteria 1-3 are major criteria

Type de données

boolean

Alias
UMLS CUI [1]
C0032131
2. bone marrow plasmacytosis (> 30% plasma cells).
Description

Bone marrow plasmacytosis

Type de données

boolean

Alias
UMLS CUI [1]
C0238803
3. monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin g (igg) > 3.5 g/dl or immunoglobulin a (iga) > 2.0 g/dl; kappa or lambda light chain excretion > 1 g/day on 24 hour urine protein electrophoresis.
Description

monoclonal immunoglobulin spike, IgG, IgA, kappa or lambda light chain excretion on 24 hour urine protein electrophoresis

Type de données

boolean

Alias
UMLS CUI [1]
C0860896
UMLS CUI [2]
C0202087
UMLS CUI [3]
C0202083
UMLS CUI [4,1]
C0021036
UMLS CUI [4,2]
C2321676
UMLS CUI [5,1]
C0021037
UMLS CUI [5,2]
C2321676
minor criteria:
Description

Minor criteria

Type de données

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C0205165
1. bone marrow plasmacytosis (10 to 30% plasma cells)
Description

following criteria 1. -4. are minor criteria

Type de données

boolean

Alias
UMLS CUI [1]
C0238803
2. monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
Description

Monoclonal immunoglobulin

Type de données

boolean

Alias
UMLS CUI [1]
C0700271
3. lytic bone lesions
Description

Lytic bone lesions

Type de données

boolean

Alias
UMLS CUI [1]
C0221204
4. normal immunoglobulin m (igm) < 50 mg/dl, iga < 100 mg/dl or igg < 600 mg/dl.
Description

IgM, IgA, IgG

Type de données

boolean

Alias
UMLS CUI [1]
C0202084
UMLS CUI [2]
C0202083
UMLS CUI [3]
C0202087
any of the following sets of criteria will confirm the diagnosis of multiple myeloma:
Description

following sets of criteria will confirm the diagnosis of multiple myeloma

Type de données

boolean

Alias
UMLS CUI [1,1]
C0026764
UMLS CUI [1,2]
C0750484
1. any two of the major criteria.
Description

Eligibility Criteria

Type de données

boolean

Alias
UMLS CUI [1]
C1516637
2. major criterion 1 plus minor criterion b, c or d.
Description

Eligibility Criteria

Type de données

boolean

Alias
UMLS CUI [1]
C1516637
3. major criterion 3 plus minor criterion a or c.
Description

Eligibility Criteria

Type de données

boolean

Alias
UMLS CUI [1]
C1516637
4. minor criteria a, b and c or a, b and d.
Description

Eligibility Criteria

Type de données

boolean

Alias
UMLS CUI [1]
C1516637
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. renal insufficiency (serum creatinine levels > 3 mg/dl).
Description

Renal insufficiency

Type de données

boolean

Alias
UMLS CUI [1]
C0201976
2. patients who present with either alt or ast ≥ 2.5 x upper limit of normal.
Description

ALT/AST

Type de données

boolean

Alias
UMLS CUI [1]
C0201836
UMLS CUI [2]
C0201899
3. history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
Description

Hypersensitivity to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine)

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0754570
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0068006
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0044549
4. concomitant therapy medications that include corticosteroids (except as indicated for other medical conditions, or up to 100 mgs of hydrocortisone as premedication for administration of certain medications or blood products) or other chemotherapy that is or may be active against myeloma, or therapy with chemotherapy within 3 weeks prior to day 1. nitrosoureas must be discontinued 6 weeks prior to day 1.
Description

Corticosteroids, other chemotherapy, nitrosoureas

Type de données

boolean

Alias
UMLS CUI [1]
C0038317
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0028210
5. subjects with a hemoglobin < 8.0 g/dl.
Description

Hb

Type de données

boolean

Alias
UMLS CUI [1]
C0518015
6. any condition, including laboratory abnormalities, that in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study.
Description

Any condition that places the subject at unacceptable risk if they were to participate in the study

Type de données

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
7. women of childbearing potential (wcbp) who are pregnant, or breast-feeding or men and women who are not using adequate contraception are excluded.
Description

Pregnant or breast feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0700589
8. plasma cell leukemia.
Description

Plasma cell leukemia

Type de données

boolean

Alias
UMLS CUI [1]
C0023484
Retour au début de la page

Similar models

Eligibility Multiple Myeloma NCT00375791

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Plasmacytomas
Item
1. plasmacytomas on tissue biopsy.
boolean
C0032131 (UMLS CUI [1])
Bone marrow plasmacytosis
Item
2. bone marrow plasmacytosis (> 30% plasma cells).
boolean
C0238803 (UMLS CUI [1])
monoclonal immunoglobulin spike, IgG, IgA, kappa or lambda light chain excretion on 24 hour urine protein electrophoresis
Item
3. monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin g (igg) > 3.5 g/dl or immunoglobulin a (iga) > 2.0 g/dl; kappa or lambda light chain excretion > 1 g/day on 24 hour urine protein electrophoresis.
boolean
C0860896 (UMLS CUI [1])
C0202087 (UMLS CUI [2])
C0202083 (UMLS CUI [3])
C0021036 (UMLS CUI [4,1])
C2321676 (UMLS CUI [4,2])
C0021037 (UMLS CUI [5,1])
C2321676 (UMLS CUI [5,2])
Minor criteria
Item
minor criteria:
boolean
C1516637 (UMLS CUI [1,1])
C0205165 (UMLS CUI [1,2])
Bone marrow plasmacytosis
Item
1. bone marrow plasmacytosis (10 to 30% plasma cells)
boolean
C0238803 (UMLS CUI [1])
Monoclonal immunoglobulin
Item
2. monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
boolean
C0700271 (UMLS CUI [1])
Lytic bone lesions
Item
3. lytic bone lesions
boolean
C0221204 (UMLS CUI [1])
IgM, IgA, IgG
Item
4. normal immunoglobulin m (igm) < 50 mg/dl, iga < 100 mg/dl or igg < 600 mg/dl.
boolean
C0202084 (UMLS CUI [1])
C0202083 (UMLS CUI [2])
C0202087 (UMLS CUI [3])
following sets of criteria will confirm the diagnosis of multiple myeloma
Item
any of the following sets of criteria will confirm the diagnosis of multiple myeloma:
boolean
C0026764 (UMLS CUI [1,1])
C0750484 (UMLS CUI [1,2])
Eligibility Criteria
Item
1. any two of the major criteria.
boolean
C1516637 (UMLS CUI [1])
Eligibility Criteria
Item
2. major criterion 1 plus minor criterion b, c or d.
boolean
C1516637 (UMLS CUI [1])
Eligibility Criteria
Item
3. major criterion 3 plus minor criterion a or c.
boolean
C1516637 (UMLS CUI [1])
Eligibility Criteria
Item
4. minor criteria a, b and c or a, b and d.
boolean
C1516637 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Renal insufficiency
Item
1. renal insufficiency (serum creatinine levels > 3 mg/dl).
boolean
C0201976 (UMLS CUI [1])
ALT/AST
Item
2. patients who present with either alt or ast ≥ 2.5 x upper limit of normal.
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
Hypersensitivity to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine)
Item
3. history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
boolean
C0020517 (UMLS CUI [1,1])
C0754570 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0068006 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0044549 (UMLS CUI [3,2])
Corticosteroids, other chemotherapy, nitrosoureas
Item
4. concomitant therapy medications that include corticosteroids (except as indicated for other medical conditions, or up to 100 mgs of hydrocortisone as premedication for administration of certain medications or blood products) or other chemotherapy that is or may be active against myeloma, or therapy with chemotherapy within 3 weeks prior to day 1. nitrosoureas must be discontinued 6 weeks prior to day 1.
boolean
C0038317 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0028210 (UMLS CUI [3])
Hb
Item
5. subjects with a hemoglobin < 8.0 g/dl.
boolean
C0518015 (UMLS CUI [1])
Any condition that places the subject at unacceptable risk if they were to participate in the study
Item
6. any condition, including laboratory abnormalities, that in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Pregnant or breast feeding
Item
7. women of childbearing potential (wcbp) who are pregnant, or breast-feeding or men and women who are not using adequate contraception are excluded.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
Plasma cell leukemia
Item
8. plasma cell leukemia.
boolean
C0023484 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial